#USA #New York #Pomerantz LLP #NPCE #NeuroPace Inc

Investor Alert: Pomerantz Law Firm Investigates NeuroPace, Inc. Claims

The Pomerantz Law Firm has initiated an investigation into the allegations surrounding NeuroPace, Inc. (NASDAQ: NPCE), focusing on the rights of investors following recent developments that could indicate serious wrongdoing. This investigation centers on whether the company and certain executives may have engaged in securities fraud or other unlawful business practices, which has raised concerns among the investor community.

Recently, on May 27, 2025, NeuroPace released a press statement regarding the preliminary results of the NAUTILUS study, assessing the safety and effectiveness of the RNS System for patients suffering from drug-resistant idiopathic generalized epilepsy. The announcement disclosed some troubling news: the study did not achieve statistical significance for its primary effectiveness endpoint. This was intended to show a longer duration before a second generalized tonic-clonic seizure occurred in patients receiving the actual stimulation compared to those who received a sham treatment.

This disappointing news had an immediate and drastic impact on NeuroPace's stock price, which plunged by $5.02, translating to a staggering 28.39% decrease, closing at $12.66 per share on the same day of the announcement. This sharp decline has prompted many investors to question the integrity of the company’s disclosures and business practices leading up to the study results.

Pomerantz LLP, with an acclaimed history in corporate law and securities class action litigation, is reaching out to affected investors. The firm is urging them to come forward to discuss their experiences and to explore their potential legal options. Danielle Peyton, a legal representative from Pomerantz, is available for inquiries at 646-581-9980, ext. 7980, or via email at [email protected] This effort highlights the commitment of Pomerantz to fight for the rights of investors who may have been misled or suffered financial losses due to inadequate disclosures or fraudulent activities.

Founded over 85 years ago by Abraham L. Pomerantz, known as the dean of class action bar, the firm has built a reputation for initiating significant litigation and securing substantial settlements in the realms of securities fraud and corporate misconduct. With offices located across major cities such as New York, Chicago, Los Angeles, and internationally in London and Tel Aviv, the firm is well-poised to handle cases of this nature, aiming to achieve justice for affected investors.

The outcome of Pomerantz’s investigation could potentially lead to a class action lawsuit, which would represent the collective interests of the affected investors. Those who have experienced losses as a result of the fluctuations in NeuroPace's stock price following the study announcement may have valid claims under securities laws.

In the arena of corporate governance, the situation with NeuroPace highlights the critical importance of accurate and timely information for investors. As the investigation unfolds, individuals are encouraged to remain vigilant and informed about their investment choices, particularly in light of the new information emerging about the company’s performance and practices.

Investors are advised to keep close tabs on this situation, as developments could have significant implications for their investments. Furthermore, the Pomerantz Law Firm's proactive approach to the matter exemplifies the essential advocacy work being done in the field of investor rights protection. As always, interested parties should consider their options carefully and seek appropriate legal guidance when dealing with complex investment issues such as these.